Novartis raises 2024 financial guidance, expecting high-teens core operating profit growth and low double-digit sales growth.
Novartis has increased its 2024 financial guidance for the third time this year, anticipating a high-teens percentage growth in core operating profit and low double-digit sales growth. In Q3, the company reported a 10% rise in net sales to $12.82 billion and a 20% increase in core operating income to $5.145 billion, surpassing analyst expectations. Key product sales and recent FDA approvals contributed to these strong results.
October 29, 2024
22 Articles